Clinical Trial Search

Primary: Veterans RAND 36-Item Health Survey (Change in Self-assessment of Functioning - Role Limitations) Due to Emotional Problems — 50.98; 47.35 score on a scale — p=.90

Primary: Number of Participants Assessed for Change in Markers of Inflammation (PAI-1) Following Treatment Compared to Baseline — 0; 0 participants

Primary: Treatment Retention — 5; 5 Participants — p==0.87

Primary: Subjective Questionnaires of Product Evaluation — 4.27; 3.86; 4.16; 4.9 units on a scale

Primary: Message Perceived Effectiveness - Persuasive Potential. — 3.57; 3.24; 3.26; 3.44 units on a scale

Primary: Change in Whole Blood NAD+ Level — -0.02; 0.06 μg/mL

Primary: Abstinence 6-months — 101; 90; 74; 103 Participants

Primary: Safety and Tolerability: Frequency and Severity of Adverse Events (CTCAE v4.03) — 0; 0; 3; 3 Participants

Primary: Number of Patients With Atrial Thrombus and a Zero ATE Score — 2; 816; 27; 2227 Participants

Primary: Number of Participants With Grade 2 and Higher Adverse Events (AEs) — 1; 1; 20; 18 Participants

Primary: Progression Free Survival — 11 months

Primary: Change in Voluntary Cough Peak Flow — 0.17; 0.51 l/s

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 7; 0 Participants

Primary: The Proportion of GLASSIA Versus Control CIT06 Subjects Achieving Insulin Independence After First Infusion of Single Donor Islets. — 0; 2; 2; 1 Participants

Primary: Rate of Enrollment — 12.5 Participants enrolled per month